Study of Amiodarone Given Before Lung Surgery to Prevent Atrial Fibrillation After Lung Resection

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Basic Trial Information

PhaseTypeStatusAgeSponsorProtocol IDs
Phase IIISupportive careActive18 and overOther2005P000376

Trial Description


Atrial fibrillation is a very common complication of pulmonary resection. Patients who develop atrial fibrillation require additional treatment and are more likely to stay in the hospital for longer period of time increasing the costs associated with the operation. We propose a randomized controlled trial to see if oral amiodarone given for one week before surgery can prevent atrial fibrillation after pulmonary resection. We plan to evaluate the incidence of atrial fibrillation in patients who received preoperative amiodarone and compare them to the incidence of atrial fibrillation in patients who did not received preoperative amiodarone.

Eligibility Criteria

Inclusion Criteria:

  • Resectable lung nodule or mass

Exclusion Criteria:

  • Allergy to amiodarone
  • Currently taking amiodarone
  • Documented atrial fibrillation within past 12 months
  • Known pulmonary fibrosis
  • Known hepatic dysfunction
  • Thyroid disease
  • 2nd or 3rd degree heart block
  • Severe SA node disease
  • Bradycardia-induced syncope
  • Pregnancy

Trial Contact Information

Trial Lead Organizations/Sponsors

Beth Israel Deaconess Medical Center

    Malcolm M DeCamp, MD, Principal Investigator
    Malcolm M DeCamp, MD
    Ph: 617-632-8386

    Trial Sites



    Beth Israel Deaconess Medical Center

    Malcolm M DeCamp, MD
    Ph: 617-632-8386

    Malcolm M DeCamp, MD
    Principal Investigator

    Link to the current record.
    NLM Identifier NCT00300495 processed this data on February 27, 2015

    Note: Information about this trial is from the database. The versions designated for health professionals and patients contain the same text. Minor changes may be made to the record to standardize the names of study sponsors, sites, and contacts. only lists sites that are recruiting patients for active trials, whereas lists all sites for all trials. Questions and comments regarding the presented information should be directed to